[go: up one dir, main page]

AU2003219277A1 - Intracellular antibodies - Google Patents

Intracellular antibodies

Info

Publication number
AU2003219277A1
AU2003219277A1 AU2003219277A AU2003219277A AU2003219277A1 AU 2003219277 A1 AU2003219277 A1 AU 2003219277A1 AU 2003219277 A AU2003219277 A AU 2003219277A AU 2003219277 A AU2003219277 A AU 2003219277A AU 2003219277 A1 AU2003219277 A1 AU 2003219277A1
Authority
AU
Australia
Prior art keywords
intracellular antibodies
intracellular
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219277A
Inventor
Maria Natividad LOBATO-CABALLERO
Terence Howard Rabbitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206043A external-priority patent/GB0206043D0/en
Priority claimed from GBGB0226727.6A external-priority patent/GB0226727D0/en
Priority claimed from GB0226723A external-priority patent/GB0226723D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of AU2003219277A1 publication Critical patent/AU2003219277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2003219277A 2002-03-14 2003-03-14 Intracellular antibodies Abandoned AU2003219277A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0206043.2 2002-03-14
GB0206043A GB0206043D0 (en) 2002-03-14 2002-03-14 Intracellular antibodies
GB0226723.5 2002-11-15
GBGB0226727.6A GB0226727D0 (en) 2002-11-15 2002-11-15 Intrabodies
GB0226727.6 2002-11-15
GB0226723A GB0226723D0 (en) 2002-11-15 2002-11-15 Antibodies for in vitro use
PCT/GB2003/001077 WO2003077945A1 (en) 2002-03-14 2003-03-14 Intracellular antibodies

Publications (1)

Publication Number Publication Date
AU2003219277A1 true AU2003219277A1 (en) 2003-09-29

Family

ID=28045958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219277A Abandoned AU2003219277A1 (en) 2002-03-14 2003-03-14 Intracellular antibodies

Country Status (2)

Country Link
AU (1) AU2003219277A1 (en)
WO (1) WO2003077945A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226723D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003282247A1 (en) * 2002-11-15 2004-06-15 Medical Research Council Anti-activated ras antibodies
GB0226729D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
KR20070110077A (en) 2005-03-10 2007-11-15 제넨테크, 인크. Methods and Compositions for Modulating Vascular Integrity
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2711691A1 (en) * 2008-01-07 2009-07-16 Patrys Limited Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
CA2741089A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
GB0911215D0 (en) 2009-06-29 2009-08-12 Univ Erasmus Medical Ct Gamma globin therapy
WO2011028950A1 (en) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened and methods of using the same
RU2012120783A (en) 2009-10-22 2013-11-27 Женентек, Инк. AXON DEGENERATION MODULATION
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011143262A2 (en) 2010-05-10 2011-11-17 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
EP2625197B1 (en) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened and methods of using the same
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
DK2981822T3 (en) 2013-05-06 2020-12-07 Scholar Rock Inc COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
AR097661A1 (en) 2013-09-17 2016-04-06 Obi Pharma Inc COMPOSITIONS OF A CARBOHYDRATE VACCINE TO INDUCE IMMUNE RESPONSES AND THEIR USES IN CANCER TREATMENT
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3094352B1 (en) 2014-01-16 2020-09-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (en) 2014-05-27 2022-05-06 アカデミア シニカ Anti-HER2 sugar-manipulated antibody group and its use
KR20240096599A (en) 2014-05-27 2024-06-26 아카데미아 시니카 Anti-cd20 glycoantibodies and uses thereof
EP3149161B1 (en) 2014-05-27 2021-07-28 Academia Sinica Fucosidase from bacteroides and methods using the same
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
KR101602870B1 (en) 2014-07-22 2016-03-21 아주대학교산학협력단 Method for Cell-penetrating and cytosol-localizing of intact immunoglobulin antibody, and use thereof
KR101602876B1 (en) * 2014-07-22 2016-03-11 아주대학교산학협력단 Method for inhibiting activated RAS using intact immunoglobulin antibody having Cell-penetrating ability and use thereof
WO2016013871A1 (en) * 2014-07-22 2016-01-28 아주대학교산학협력단 Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same
AU2015315294B2 (en) 2014-09-08 2020-09-17 Academia Sinica Human iNKT cell activation using glycolipids
ES2731876T3 (en) * 2014-10-23 2019-11-19 Singh Molecular Medicine Llc Single domain antibodies against intracellular antigens
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
ES2941897T3 (en) 2014-11-12 2023-05-26 Seagen Inc Compounds that interact with glycans and procedures for use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
KR102691114B1 (en) 2015-01-24 2024-08-01 아카데미아 시니카 Novel glycan conjugates and methods of using them
CN107614521B (en) 2015-01-30 2022-02-08 台湾地区“中央研究院” Universal glycoform compositions and methods for enhancing antibody efficacy
HK1244512A1 (en) 2015-02-04 2018-08-10 健泰科生物技术公司 Mutant smoothened and methods of using the same
HK1256912A1 (en) 2015-09-04 2019-10-04 台湾浩鼎生技股份有限公司 Glycan arrays and method of use
TWI746473B (en) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (en) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 Antibodies, pharmaceutical compositions and methods
RU2018140976A (en) 2016-04-22 2020-05-22 Оби Фарма, Инк. CANCER IMMUNOTHERAPY BY IMMUNE ACTIVATION OR IMMUNE MODULATION THROUGH GLOBO SERIES ANTIGENS
CA3025757A1 (en) 2016-05-27 2017-11-30 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (en) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 Human Antibodies, Pharmaceutical Compositions and Methods
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD FOR USE
KR20190077103A (en) 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 Conjugated biological molecules, pharmaceutical compositions and methods
JP2020510671A (en) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド Glycan interacting compounds and methods of use
EP3804759A4 (en) 2018-06-06 2022-07-20 Osaka University METHOD OF TREATING AND/OR PREVENTING REGNASE-1 RELATED DISEASES
KR20190143826A (en) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 Cell/tissue-specific cell-penetrating antibodies
TW202504930A (en) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 Glycosynthase variants for glycoprotein engineering and methods of use
JPWO2024143442A1 (en) 2022-12-27 2024-07-04

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP1242457B1 (en) * 1999-12-28 2004-08-11 Esbatech AG Intrabodies with defined framework that is stable in a reducing environment and applications thereof
JP2004538324A (en) * 2001-08-03 2004-12-24 メディカル リサーチ カウンシル Intracellular antibody

Also Published As

Publication number Publication date
WO2003077945A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
AU2003219277A1 (en) Intracellular antibodies
AU2003217912A1 (en) Antibody optimization
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2003233465A1 (en) Structural member
AU2003274037A1 (en) 1-phenylpyrrolidine-2-one-3-carboxamides
AU2003280511A1 (en) Vibrator
AU2003239197A1 (en) Novel stable anti-cd22 antibodies
AU2002952554A0 (en) Monitower
AU2003212773A1 (en) Boosterantenna
AU2002255105A1 (en) Intracellular analysis
AU2003208685A1 (en) Podologic aid
AU2002318053A1 (en) Suplier
AU2003270055A1 (en) Neurotransmission-associated proteins
AU2003205935A1 (en) Forming means
AU2003300785A1 (en) Carbohydrate-associated proteins
GB0206043D0 (en) Intracellular antibodies
GB0200928D0 (en) Intracellular antibodies
GB0203569D0 (en) Intracellular antibodies
HK1087130A (en) Antibodies
AU2003236908A1 (en) Proteins
AU2003295760A1 (en) Organelle-associated proteins
AU2003238461A1 (en) Assays
AUPS186702A0 (en) Backpack
AU2002951647A0 (en) Cyclospora antibodies
AU2002100739A4 (en) Neuramax

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase